Brief: Naya Biosciences And Onk Therapeutics Announce Research Partnership To Advance Combination Therapy Of Flex-NK™ Bispecific Antibodies And Optimally Engineered Off-The-Shelf Natural Killer Cell Therapies
06/12/2023 14:07
Dec 6 (Reuters) - INVO Bioscience Inc INVO.O :
* NAYA BIOSCIENCES AND ONK THERAPEUTICS ANNOUNCE RESEARCH
PARTNERSHIP TO ADVANCE COMBINATION THERAPY OF FLEX-NK™
BISPECIFIC ANTIBODIES AND OPTIMALLY ENGINEERED OFF-THE-SHELF
NATURAL KILLER CELL THERAPIES
Source text for Eikon: ID:nPn7VQGrfa
Further company coverage: INVO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on INVO Fertility
See all newsINVO Fertility Q2 revenue rises, partly on acquisitions
Invo Fertility Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Invo Fertility Inc Expected To Post A Loss Of 70 Cents A Share: Earnings Preview
Brief: INVO Fertility - Entered Into Any Market Purchase Agreement With Alumni Capital Lp
Invo Fertility Inc Reports Results For The Quarter Ended March 31: Earnings Summary